Research programme: genetic disorder therapeutics - BioBlast Pharma

Drug Profile

Research programme: genetic disorder therapeutics - BioBlast Pharma

Alternative Names: BB-FA; BB-OTC; BBrm 01; BBrm02; BBrm1; Intrathecal azithromycin - BioBlast

Latest Information Update: 14 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioblast Pharma
  • Class Macrolides; Proteins; Small molecules
  • Mechanism of Action Frataxin protein replacements; Gene expression modulators; Ornithine carbamoyltransferase replacements; Survival of motor neuron 2 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Friedreich's ataxia; Inborn urea cycle disorders; Spinal muscular atrophy

Most Recent Events

  • 22 Jun 2015 Pharmacodynamics data from a preclinical trial in spinal muscular atrophy released by BioBlast Pharma
  • 22 Jun 2015 BioBlast plans a phase IIa trial for Spinal muscular atrophy in USA
  • 26 Mar 2015 Pharmacodynamics data from preclinical trial in Friedreich's ataxia released by BioBlast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top